#USA #Phoenix #BioLab Holdings #mimiX AWC #FastSkin Patch

BioLab Holdings Enhances Healing with FastSkin® Autologous Technology

In the ever-evolving medical technology landscape, BioLab Holdings, Inc. is stepping forward with a notable addition to its tissue restoration portfolio. Based in Phoenix, this pioneer in advancing healthcare solutions has recently announced its strategic partnership with mimiX AWC, a company committed to regenerative medicine. This collaboration aims to introduce the FastSkin® Patch—a significant innovation in wound care technology.

A New Era in Wound Care

BioLab's partnership with mimiX AWC marks an important milestone as it enhances BioLab's offerings with a new system designed to utilize the body’s own biological resources for effective wound care. FastSkin® Patch employs a transformative Whole Blood Clot technology, which is an advanced evolution of traditional treatments like platelet-rich plasma (PRP) and platelet-rich fibrin (PRF). This cutting-edge method presents clinicians with a portable and comprehensive solution that can be deployed directly at various care sites, allowing for timely and efficient patient treatment.

FastSkin® Patch stands out in its capabilities, producing highly effective PRP-based therapies that are clinically practicable in mobile and point-of-care environments. Within approximately 10 minutes, a personalized bioactive tissue is created from the patient's own blood, offering a quick and robust approach for managing chronic and hard-to-heal wounds.

Supporting Clinicians and Patients Alike

Jaime Leija, President and CEO of BioLab Holdings, emphasized that, "At BioLab, we believe the best clinicians don't want one answer but the best answer." This ethos is embodied in the FastSkin® Patch technology. Apart from enhancing the existing product lineup, it offers healthcare professionals another powerful tool to facilitate healing and improve patient outcomes.

Designed specifically for handling various types of exuding cutaneous wounds—such as diabetic ulcers, pressure ulcers, venous leg ulcers, and surgically debrided wounds—FastSkin® Patch promotes the formation of a whole blood clot, enriched with natural cellular and biological components essential for healing. The user-friendly preparation process consists merely of a simple blood draw, negating the need for costly equipment and ensuring seamless integration into existing clinical workflows.

A Mission of Innovation

Marc Thurner, the CEO of mimiX AWC, expressed his enthusiasm for the collaboration, stating, "Our mission is to advance wound care through science-driven innovation that works in harmony with the body's own healing processes." The partnership with BioLab not only amplifies the reach of FastSkin® Patch but also underlines a shared commitment to enhancing patient care and providing practical, effective regenerative solutions.

As BioLab continues to build one of the most comprehensive tissue restoration portfolios in the industry, this alliance not only showcases their innovative spirit but also emphasizes the importance of collaboration in the advancement of medical technologies.

With its robust commercialization network, BioLab Holdings is gearing up to roll out the FastSkin® Patch across diverse wound care settings nationwide. For healthcare professionals seeking to adopt advanced wound management solutions, BioLab’s approach promises enhanced patient care through its commitment to creating practical, effective technologies.

For comprehensive information about their continuum of care, you can visit their official site at biolabholdings.com and explore more on mimiX AWC and the FastSkin® Patch at mimix-awc.com.